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Predictors of Overall ST HR 95% CI p value
Recent MI up to 72 hours 2.66 1.52-4.66 0.001
Recent MI >72 hours 1.89 1.08-3.29 0.03
Multiple DES implanted 1.89 1.28-2.80 0.002
SVG 2.21 1.29-3.78 0.004
Residual stenosis (QCA analysis) 1.03 1.00-1.05 0.03
Predictors of Deﬁnite ST
Recent MI up to 72 hours 3.68 1.87-7.23 <0.001
Multiple DES implanted 2.24 1.30-3.86 0.004
SVG 2.62 1.32-5.22 0.006
Predictors of Early ST (up to 30 days)
OR 95% CI p value
Diabetes 2.45 0.014
Recent MI up to 72 hours 3.65 <0.001
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The Optimal Strategy for Restenosis With Stent Fracture After Drug-Eluting
Stent Implantation: Plain Old Balloon Angioplasty vs. Paclitaxel-Coated Balloon
vs. Drug-Eluting Stent
Suguru Otsuru1, Kazushige Kadota1, Shunsuke Kubo1, Yusuke Hyodo1,
Daiji Hasegawa1, Seiji Habara1, Takeshi Tada1, Hiroyuki Tanaka1, Yasushi Fuku1,
Tsuyoshi Goto1, Kazuaki Mitsudo1
1Kurashiki Central Hospital, Kurashiki, Japan
Background: Stent fracture is related to restenosis after drug-eluting stent (DES) im-
plantation. As percutaneous coronary intervention (PCI) cases for complex lesions
increased, those for stent fracture-related restenosis also increased. However, the optimal
PCI strategy for such restenosis remains unclear. We compared the results of PCI with
plain old balloon angioplasty (POBA), paclitaxel-coated balloon (PCB), and DES (siro-
limus-eluting stent, paclitaxel-eluting stent, zotarolimus-eluting stent, everolimus-eluting
stent, and biolimus-eluting stent) for restenosis with stent fracture after DES implantation.
Methods: From November 2002 to December 2012, 9357 patients with 15894 lesions
underwent DES implantation successfully. Of these, 12918 lesions were angio-
graphically followed up after 6 to 8 months (midterm f/u) and 9989 were followed up
at 12 months after midterm f/u. Stent fracture occurred in 576 (4.5%) of the 12918
lesions and restenosis with stent fracture occurred in 206 lesions. Restenosis with stent
fracture was deﬁned as a restenosis lesion within 5 mm from a stent fracture site. Of
the 206 lesions, target lesion revascularization by PCI with POBA, PCB, or DES was
performed on 124 lesions.
Results: Data are shown in the ﬁgure. At 2-year f/u, the cumulative incidence of re-
restenosis was signiﬁcantly lower after retreatment with DES than that with POBA
and PCB. In addition, late catch-up phenomenon was found after retreatment with
PCB.JACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/CoConclusions: Retreatment with DES could be an acceptable treatment for restenosis
with stent fracture after DES implantation.
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Outcomes After Repeat Intervention With Everolimus-eluting Stent For
Sirolimus-eluting Stent Restenosis Lesion With Stent Fracture
Yasunari Sakamoto1, Toshiya Muramatsu1, Reiko Tsukahara1, Yoshiaki Ito1,
Hiroshi Ishimori1, Keisuke Hirano1, Masatsugu Nakano1, Masahiro Yamawaki1,
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Background: Presence of stent fracture (SF) after sirolimus-eluting stent (SES) im-
plantation has reported to be associated with an increased risk of adverse events and
those are previously reported. But little is known about the outcomes after re-inter-
vention for SES restenosis lesion with SF.
Methods: From April 2007 to August 2011, total 2059 lesions implanted SES during
PCI at our hospital. Total 228 lesions, 11.1% had restenosis (deﬁned as %diameter
stenosis >50%) in follow-up angiogram until March 2013. Subjects of the study were
49 lesions 42 patients those implanted SES for denovo coronary artery stenosis and in-
stent restenosis with SF was documented in follow-up angiogram. SF was deﬁned as
complete or partial separation of the stent as assessed by plain ﬂuoroscopy. During the
target lesion revascularization procedure, 14 lesions implanted everolimus-eluting
stent (EES group), 20 lesions implanted sirolimus- and paclitaxel-eluting stent,
stainless steel stent with durable polymer (SS group). And also 15 lesions were dilated
with balloon angioplasty alone (POBA group). We compared the outcomes of
3 groups retrospectively.
Results: Baseline characteristics were similar. One-year cumulative incidence of
restenosis after repeat intervention those calculated by Kaplan-Meier methods were
EES group 22%, SS group 66% and POBA group 76%, respectively. EES group
signiﬁcantly reduced the cumulative incidence of restenosis after repeat intervention
(versus SS group; p¼0.0471 and POBA group; p¼0.0085).
Conclusions: For reduction in incidence of re-restenosis for the SES restenosis lesion
with SF during 1-year after repeat intervention, cobalt chromium EES implantations
were superior to stainless steel stent with durable polymer or balloon angioplasty
alone.
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Background: Stent fracture (SF) is an unresolved, clinically relevant issue, even in
the newer-generation drug-eluting stent era. The PROMUS Element platinum-chro-
mium everolimus-eluting stent (PtCr-EES; Boston Scientiﬁc, Natick, Massachusetts)
is designed to provide the improved fracture resistance, whereas the incidence and
clinical impact of SF after PtCr-EES implantation remains unclear. The aim of this
study was to assess the incidence and clinical impact of SF after PtCr-EES
implantation.
Methods: Between March 2012 and June 2013, a total of 676 patients with 839 le-
sions undergoing PtCr-EES implantation and follow-up angiography within 9 months
after index procedure were analyzed. SF was deﬁned as complete or partial separation
of the stent, as assessed by plain ﬂuoroscopy, intravascular ultrasound, or optical
coherence tomography during the follow-up. We assessed the rate of SF and the
cumulative incidence of clinically-driven target lesion revascularization and deﬁnite
stent thrombosis within 9 months.
Results: SF was observed in 12 of 839 lesions (1.4%) and 12 of 676 patients (1.7%).
Cumulative incidence of clinically-driven target lesion revascularization within 9
months was numerically higher in the SF group than that in the non-SF group (25.0%
versus 2.4%). Cumulative incidence of deﬁnite early and late stent thrombosis within
9-month was similar between the SF and non-SF groups (0.0% versus 0.2%).
Conclusions: SF after PtCr-EES occurs in 1.4% of lesions and appears to be asso-
ciated with clinically-driven target lesion revascularization.
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Background: Stent fracture (SF) after DES implantation has recently become an
important concern because of its potential association with in-stent restenosis and stent
thrombosis. However, the incidence and clinical relevance to SF after second gener-
ation DES (zotarolimus-eluting stent: ZES, everolimus-eluting stent: EES, and bio-
limus-eluting stent: BES) remain unclear, so the aim of study is to reveal clinical
impact of SF after second generation DES deployment.
Methods: A total of 1734 patients with 2185 lesions undergoing second generation
DES implantation and follow-up angiography within 12 months were performed from
April 2009 to September 2012 in a single center. We divided into SF group and non-
SF group and assessed the rates of SF and major adverse cardiac events (MACE),
deﬁned as death, myocardial infarction, stent thrombosis, and target lesion revascu-
larization (TLR), retrospectively.
Results: We had obtained 1826 lesions follow-up angiography. (83.6%) The mean
clinical follow up period was 78815 days. There were no signiﬁcant differences in
patient background and lesion characteristics except HD. (SF group: 30.4% versus
non-SF group: 4.2%; p< 0.001) However, there was no signiﬁcant difference in the
calciﬁcation lesion between the two group. (N.S.) SF was observed in 26 of 1823
lesions (1.4%). The rate of TLR and late stent thrombosis were signiﬁcantly higher in
the SF group than in the non-SF group (33.3% versus 5.4%; p< 0.001 and 3.7%
versus 0.1%; p¼0.02). MACE was signiﬁcantly higher in the SF group than in the
non-SF group (44.4% versus 10.9%; p< 0.001).
Conclusions: SF after second generation DES implantation occurs in 1.4% of lesions
and is associated with higher rate of TLR, MACE, and late stent thrombosis.
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Background: We aimed to evaluate the incidence and predictors of late catch-up
phenomenon after ﬁrst and second generation drug-eluting stent (DES) implantations.
Methods: From 2002 to 2012, 10996 lesions received DES implantation: ﬁrst gen-
eration, 6242 sirolimus-eluting stents (SES); second generation, 3391 everolimus-
eluting stents (EES) and 1363 biolimus-eluting stents (BES). Mid-term angiographic
follow-up was scheduled at 8 months and late-term at 20 months. We analyzed 6849
lesions (SES, 3871; EES, 2153; and BES, 825) after late-term follow-up, which were
free from in-stent restenosis (ISR) and target lesion revascularization at mid-term
follow-up. ISR was deﬁned as restenosis >50% and late catch-up phenomenon as the
ﬁrst ISR over one year after DES implantation. The follow-up duration was two years.
Results: The late catch-up phenomenon rate was not signiﬁcantly different between
EES and SES (5.8% vs. 7.1%, p¼0.06) but signiﬁcantly lower in BES than in SES
(4.4% vs. 7.1%, p¼0.004). The predictors of late catch-up phenomenon (p< 0.10,
univariate analysis) were hypertension, diabetes, hemodialysis, ostial lesion in the
right coronary artery or in the left circumﬂex artery, ISR lesion, reference diameter
< 2.5 mm, percent diameter stenosis before (>75%) or after (>25%) DES implan-
tation, angulated lesion, lesion length >30 mm, chronic total occlusion lesion, left
main trunk stenting, and DES types, from which 10 variables in the ﬁnal multivariable
regression model obtained by the forward stepwise method are shown in the table.Conclusions: BES implantation is a negative predictor of late catch-up phenomenon.
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non-target lesion (TL) segments and the process of in-stent neoatherosclerosis (NA)
ﬁve years after DES implantation is unknown.
Methods: The SIRTAX-LATE OCT population was analyzed for evidence of in-stent
NA as assessed by OCT ﬁve years after DES (sirolimus-eluting stent (SES) and
paclitaxel-eluting stent (PES)) implantation. NA was deﬁned as the presence of
ﬁbrocalciﬁc plaques or ﬁbroatheromas within the neointima of previously implanted
DES with longitudinal extension of >1.5mm. Native coronary artery disease pro-
gression in non-TL segments was evaluated by serial quantitative coronary angiog-
raphy (QCA) in all arterial segments with diameter of at least 1.5mm and length of at
least 10mm. The minimal lumen diameter (MLD) was serially assessed within
matched segments at baseline and ﬁve year angiographic follow-up, or prior to any
non-TL revascularization. The change in MLD between baseline and follow-up was
calculated as endpoint related to angiographic disease progression. The clinical
endpoint was any non-TL revascularization assessed throughout 5 years by an inde-
pendent clinical event committee.
Results: A total of 88 patients with 88 lesions were available for OCT analysis 5 years
after DES implantation. In-stent neoatherosclerosis was observed in 14% of all stented
segments with the majority of patients having ﬁbroatheromas (12.5%) followed by
ﬁbrocalciﬁc plaques (5.6%). A total of 716 untreated native coronary artery segments
(8.11.7 segments/patient) were serially evaluated by QCA. The change in MLD
between baseline and ﬁve year angiographic follow-up was signiﬁcantly higher in
patients with OCT evidence of NA (0.25mm, 95%CI 0.15-0.35) as compared with
patients without evidence of NA (0.13mm, 95%CI 0.09-0.17, p¼0.002). Consistent
with the angiographic ﬁndings, any revascularization in non-TL segments occurred
more frequently in patients with evidence of NA (79%) as compared with patients
without evidence of NA (47%, p¼0.02).
Conclusions: Patients with angiographic and clinical evidence of native coronary
artery disease progression in non-TL segments are more likely to develop in-stent
neoatherosclerosis.
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Background: Neoatherosclerosis after drug eluting stent (DES) implantation is
known to be related with increased risk of late restenosis and stent thrombosis. Studies
have suggested that inﬂammation by polymer may be one of several mechanisms, but
there have been a few data about bioabsorbable polymer DES (BP-DES) versus du-
rable polymer DES (DP-DES). The aim of study is to compare neoatherosclerosis and
relevant clinical outcomes between BP-DES and DP-DES by Optical Coherence
Tomography (OCT) analysis.
Methods: A total of 292 patients undergoing OCT analysis after DES implantation
were enrolled, who were divided into 2 groups according to stent type [BP-DES
(n¼107) and DP-DES (n¼185)]. OCT analysis was performed within 2 years after
stent implantation. Neoatherosclerosis was deﬁned as presence of more or 1 of as
followings; plaque rupture, thrombus, neovascularization, plaque erosion, micro-
vessel, macrophage and thin of thick ﬁbrous cap atheroma. The primary end point was
the incidence of neoatherosclerosis, and the secondary end point was the occurrence of
MACE (major advanced cardiac events; death, myocardial infarction, target lesion
revascularization, or stent thrombosis).
Results: Demographic, clinical, lesional and procedural characteristics were not
signiﬁcantly different between the two groups. The incidence of neoatherosclerosis
was lower in the BP-DES group than in the DP-DES group (16.8% vs. 30.8%,
p¼0.008). The rate of MACEs did not show signiﬁcant difference between two groups
(9.3% vs. 14.7%, p¼0.208). The Incidence of neoatherosclerosis was not signiﬁcantly
different at 1 year but was lower in BP-DES group than in the DP-DES group between
1 and 2 years (13.9% vs. 29.8%, p¼0.007).
Conclusions: In this 2 year follow-up study, patients undergoing BP-DES implan-
tation had lower rates of neoatherosclerosis than patient with DP-DES, but it did not
translate into better clinical outcomes.
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Background: In-stent neoatherosclerosis has emerged as an important contributing
factor for late stent failure including very late stent thrombosis (VLST) and restenosis.
Clinical imaging modalities, however, have limited capability of evaluating the
presence and characteristics of neoatherosclerosis. The aim of the current pathologic
study was to investigate the prevalence of neoatherosclerosis in lesions with late stentr 13–17, 2014 j TCT Abstracts/Coronary Lesions - In-stent Restenosis
